Abstract: There is described herein a method of predicting disease progression risk in a subject with prostate cancer, the method comprising: a) providing a sample containing RNA and DNA material from tumour cells; b) determining or measuring values for substantially all of patient features listed for PRONTO-e or PRONTO-m in Table 6, and some or all reference or control features set forth in Table 6; c) comparing said patient features to the reference or control features; and d) computing a prediction score using a classifier that takes said patient feature values as input, the classifier having been previously trained on samples from a population of early prostate cancer patients.

Abstract: A method of protecting a patient from possible adverse effects of a treatment involving inhibition of the SHH-signalling pathway in the patient, the method comprising suppressing testosterone or its effect in the patient. A method of treating a proliferative disease such as cancer in a patient the method comprising inhibiting the SHH-signalling pathway and suppressing testosterone or its effect in the patient. Typically, the SHH-signalling pathway is inhibited using cyclopamine or a derivative thereof, and testosterone is suppressed using any one or more of a GnRH antagonist, a GnRH agonist, an androgen antagonist or a Sa-reductase inhibitor.